Cite
HARVARD Citation
Atreya, R. et al. (n.d.). DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Journal of Crohn's and colitis. pp. i126-i127. [Online].